FLAURA2 trial finds minimal impact of osimertinib on quality of life in EGFR-mutated lung cancer patients, suggesting limited benefit of treatment combinations.
In FLAURA2, osimertinib monotherapy and combination with platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.
No takes yet. Share an insight, caveat, or question.
Gray et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: